Intraperitoneal antineoplastic drug delivery: Rationale and results

Lancet Oncology

Volumn 4, Issue 5, 2003, Pages 277-283

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; REVIEW; THEORY; THROMBOCYTOPENIA; TINNITUS; VOMITING;

EID: 0038632303     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01074-X     Document Type: Review

References (62)

1. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955; 159: 1704-07.
2. Ostrowski MJ. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 1986; 57: 721-27.
3. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-9.
4. Alberts DS, Young L, Mason N, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985; 12 (Suppl 4): 38-42.
5. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 1993; 14: 15-28.
6. Howell SB, Pfeifle CE, Wong WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845-51.
7. Casper ES, Kelsen DP, Alcock NW, et al. Ip cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with the iv route. Cancer Treat Rep 1983; 67: 325-38.
8. DeGregorio MW, Lum BL, Holleran WM, et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1986; 18: 235-38.
9. Elferink F, van der Vijgh WJF, ten Bokkel Huinink WW, et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988; 21: 57-60.
10. Markman M, Rowinsky E, Hakes T, et al. Phase 1 trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-91.
11. Francis P, Rowinsky E, Schneider L et al. Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13: 2961-67.
12. Ozols RF, Young RC, Speyer JL, et al. Phase 1 and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982; 42: 4265-69.
13. Alberts DS, Surwit EA, Peng Y-M, et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 1988; 48: 5874-77.
14. West GW, Weichselbau R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665-68.
15. Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 1981; 41: 3495-98.
16. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39: 3209-14.
17. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984; 13: 131-35.
18. Los G, Mutsaers PHA, van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380-84.
19. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801-05.
20. Markman M, Berek JS, Blessing JA, et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992; 45: 3-8.
21. Markman M, Blessing JA, Major F, et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Gynecol Oncol 1993; 50: 191-95.
22. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 2620-24.
23. Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol Hematol 1999; 31: 239-46.
24. Braly PS, Berek IS, Blessing JA, et al. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial. Gynecol Oncol 1995; 56: 164-68.
25. Markman M, George M, Hakes T, et al. Phase 2 trial of intraperitoneal mitoxantrone in the management of refractory ovarian carcinoma. J Clin Oncol 1990; 8: 146-50.
26. Berek JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 1999; 75: 10-14.
27. Pujade-Lauraine E, Guastalla J-P, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14: 343-50.
28. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15: 3399-407.
29. Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990; 36: 306-11.
30. Speyer JL, Beller U, Colombo N, et al. Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990; 8: 1335-41.
31. Howell SB, Zimm S, Markman M, et al. Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607-12.
32. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically-defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol 1992; 10: 1479-84.
33. Piver MS, Recio FO, Baker TR, et al. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 1994; 73: 1693-98.
34. Barakat R, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up in 411 patients. J Clin Oncol 2002; 20: 694-98.
35. Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998; 69: 17-22.
36. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-55.
37. Markman M, Bundy BN, Alberts DS, et al. Randomized phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume small III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-07.
38. Shapiro F, Schneider J, Markman M, et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol 1997; 67: 39-45.
39. Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial. Proc Am Soc Clin Oncol 2002; 21: 201a
40. Davidson SA, Rubin SC, Markman M, et al. Intraperitoneal chemotherapy: analysis of complications with an implantable subcutaneous port and catheter system. Gynecol Oncol 1991; 41: 101-06.
41. Kaplan RA, Markman M, Lucas WE, et al. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 1985; 78: 49-53.
42. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
43. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
44. Markman M, Reichman B, Hakes T, et al. Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1992; 47: 353-57.
45. Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol Oncol 1993; 50: 100-04.
46. Los G, Verdegaal EME, Mutsaers PHA, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159-65.
47. Sugarbaker PH, Gianola FJ, Speyer JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985; 98: 414-21.
48. Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629-31.
49. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16: 2733-38.
50. Wansik Y, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-54.
51. Sugarbaker PH, Zhu B-W, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993; 36: 323-29.
52. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-76.
53. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis. Cancer 2002; 94: 492-99.
54. Markman M, Cleary S, Pfeifle CE, et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986; 58: 18-21.
55. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118: 547-50.
56. Antman KH, Klegar KL, Pomfret EA, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985; 2: 977-80.
57. Lederman GS, Recht A, Herman T, et al. Long-term survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer 1987; 59: 1882-86.
58. Markman M. Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Cancer Invest 1995; 13: 625-28.
59. Ronnett, BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92: 85-91.
60. Conway JG, Popp JA, Ji S, Thurman RG. Effect of size on portal circulation of hepatic nodules from carcinogen-treated rats. Cancer Res 1983; 43: 3374-79.
61. Lin G, Lunderquist A, Hagerstrand I, Boijsen E. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 1984; 96: 517-26.
62. Markman M. The intracavitary administration of biological agents. J Biol Response Mod 1987; 6: 404-11.